Discover
ANB019 / AnaptysBioANB019 regulatory estimate: Approval for palmo-plantar pustular psoriasis in US/EU in 2022 (Jefferies) - Sep 11, 2019 - A subscription to Thomson ONE is required to gain full access to report 67790601; Page no: 2; REPORT TITLE: "AnaptysBio Inc - Q2' 19: Key readouts approaching to the end of the year”; AUTHOR: Amin, Biren, et al; DATE: 08/08/2019ANB019 / AnaptysBioANB019 regulatory estimate: Approval for generalized pustular psoriasis in US in 2021 and EU in 2022 (Jefferies) - Sep 11, 2019 - A subscription to Thomson ONE is required to gain full access to report 67790601; Page no: 2; REPORT TITLE: "AnaptysBio Inc - Q2' 19: Key readouts approaching to the end of the year”; AUTHOR: Amin, Biren, et al; DATE: 08/08/2019Tremfya (guselkumab) / J&JJanssen submits application to U.S. FDA seeking first-in-class approval of Tremfya (guselkumab) for treatment of adults with active psoriatic arthritis (PRNewswire) - Sep 16, 2019 - "The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking first-in-class approval of TREMFYA (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)....Janssen also expects to submit a marketing application to the European Medicines Agency seeking approval of TREMFYA as a treatment for PsA before the end of the year."ANB019 / AnaptysBioANB019 clinical trial estimate: Data from P2 GALLOP trial (NCT03619902) for generalized pustular psoriasis in Q4 2019 (Wedbush) - Sep 11, 2019 - A subscription to Thomson ONE is required to gain full access to report 67796743; Page no: 2; REPORT TITLE: "AnaptysBio Inc - 2Q19 financials; Topline ANB019 data imminent, Ph 2b atopic derm data in Q4”; AUTHOR: Nierengarten, David, et al; DATE: 08/09/2019Otezla (apremilast) / AmgenOtezla sales projection: $2.1B in 2020 (CFRA) - Sep 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 67896905; Page no: 5; REPORT TITLE: "Amgen Inc.”; AUTHOR: Huang, Kevin, et al; DATE: 08/31/2019Stelara (ustekinumab) / J&JSerum Institute unveils ₹4,000-cr plant in Pune (The Hindu Business Line) - Sep 9, 2019 - "Union Health Minister...on Monday inaugurated Serum Institute of India’s (SII) new plant with an investment of ₹4,000 crore at Manjri in Pune. The new unit, which will commence operations from November...The unit is built in compliance with the US and European vaccine manufacturing regulations....It will maximise the production of...monoclonal antibodies like...Ustekinumab (Stelara®)."Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi WW sales projection: $300M in FY2019 and $800M in FY2020 (Piper Jaffray) - Sep 9, 2019 - A subscription to Thomson ONE is required to gain full access to report 67909429; Page no: 1; REPORT TITLE: "Abbvie Inc - Skyrizi En Fuego - New derm survey indicates Q219 was no fluke”; AUTHOR: Raymond, Christopher, et al; DATE: 09/04/2019Cosentyx (secukinumab) / Novartis; Taltz (ixekizumab) / Eli Lilly; Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko KirinAllianceRx Walgreens Prime study demonstrates increased adherence and improvement in symptoms for psoriasis patients switching to interleukin-17 inhibitors (PRNewswire) - Sep 11, 2019 - "AllianceRx Walgreens Prime announced results from a new study analyzing data from patients prescribed interleukin-17 (IL-17) inhibitors for psoriasis. Patients reported improvements in psoriatic symptoms and demonstrated increased medication adherence after switching to one of the three IL-17 medications included in the study....Studies have shown that inhibiting IL-17 can help clear psoriasis. Newer biologic medications, such as secukinumab, ixekizumab or brodalumab, focus on inhibiting IL-17."
